DOCSLIB.ORG

Immunisation Registers in Europe and Elsewhere

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Europe’s journal on infectious disease epidemiology, prevention and control © Eurosurveillance,© 2012 Special edition: Immunisation registers in Europe and elsewhere April 2012 • This special edition of Eurosurveillance presents experiences with immunisation registers from six European countries, Australia and Canada. It illustrates opportunities and challenges of such systems, as well as alternative solutions that may be available in the absence of registers. www.eurosurveillance.org Editorial team Editorial advisors Based at the European Centre for Albania: Alban Ylli, Tirana Disease Prevention and Control (ECDC), Austria: Reinhild Strauss, Vienna 171 83 Stockholm, Sweden Belgium: Koen De Schrijver, Antwerp Telephone number Belgium: Sophie Quoilin, Brussels +46 (0)8 58 60 11 38 or +46 (0)8 58 60 11 36 Bosnia and Herzogovina: Nina Rodić Vukmir, Banja Luka Fax number Bulgaria: Mira Kojouharova, Sofia +46 (0)8 58 60 12 94 Croatia: TBC, Zagreb Cyprus: Chrystalla Hadjianastassiou, Nicosia E-mail Czech Republic: Bohumir Križ, Prague [email protected] Denmark: Peter Henrik Andersen, Copenhagen Editor-in-chief England and Wales: TBC, London Ines Steffens Estonia: Kuulo Kutsar, Tallinn Finland: Outi Lyytikäinen, Helsinki Scientific editors France: Judith Benrekassa, Paris Kathrin Hagmaier Germany: Jamela Seedat, Berlin Williamina Wilson Greece: Rengina Vorou, Athens Karen Wilson Hungary: Ágnes Csohán, Budapest Assistant editors Iceland: Haraldur Briem, Reykjavik Alina Buzdugan Ireland: Lelia Thornton, Dublin Ingela Söderlund Italy: Paola De Castro, Rome Associate editors Kosovo (under UNSCR 1244/99): Lul Raka, Pristina Andrea Ammon, Stockholm, Sweden Latvia: Jurijs Perevoščikovs, Riga Tommi Asikainen, Frankfurt, Germany Lithuania: Milda Zygutiene, Vilnius Mike Catchpole, London, United Kingdom Luxembourg: Thérèse Staub, Luxembourg Denis Coulombier, Stockholm, Sweden The FYR of Macedonia: Elisaveta Stikova, Skopje Christian Drosten, Bonn, Germany Malta: Tanya Melillo Fenech, Valletta Karl Ekdahl, Stockholm, Sweden Netherlands: Paul Bijkerk, Bilthoven Johan Giesecke, Stockholm, Sweden Norway: Hilde Klovstad, Oslo Herman Goossens, Antwerp, Belgium Poland: Malgorzata Sadkowska-Todys, Warsaw David Heymann, London, United Kingdom Portugal: Isabel Marinho Falcão, Lisbon Heath Kelly, Melbourne, Australia Romania: Daniela Pitigoi, Bucharest Irena Klavs, Ljubljana, Slovenia Serbia: Tatjana Pekmezovic, Belgrade Karl Kristinsson, Reykjavik, Iceland Scotland: Norman Macdonald, Glasgow Daniel Lévy-Bruhl, Paris, France Slovakia: Lukáš Murajda, Martin Richard Pebody, London, United Kingdom Slovenia: Alenka Kraigher, Ljubljana Panayotis T. Tassios, Athens, Greece Spain: Elena Rodríguez Valín, Madrid Hélène Therre, Paris, France Sweden: Christer Janson, Stockholm Henriette de Valk, Paris, France European Commission: Paolo Guglielmetti, Luxembourg Sylvie van der Werf, Paris, France World Health Organization Regional Office for Europe: Nedret Emiroglu, Copenhagen Design / Layout Fabrice Donguy / Arne Haeger www.eurosurveillance.org © Eurosurveillance, 2012 Contents Special edition: Immunisation registers in Europe and elsewhere Immunisation registers Editorials Research Articles Immunisation registers – important for vaccinated Immunisation registers in Italy: a patchwork of individuals, vaccinators and public health 2 computerisation 60 by K Johansen, PL Lopalco , J Giesecke by V Alfonsi, F D’Ancona, MC Rota, C Giambi, A Ranghiasci, S Iannazzo, Regional coordinators for infectious diseases and Vaccine registers – experiences from Europe vaccinations and elsewhere 5 by R Pebody Surveillance and outbreak reports Perspectives Use of the vaccination register to evaluate influenza vaccine coverage in seniors in the 2010/11 influenza Measuring childhood vaccine coverage in England: season, Navarre, Spain 66 the role of Child Health Information Systems 8 by I Aguilar, M Reyes, I Martínez-Baz, M Guevara, E Albéniz, by G Amirthalingam, J White, M Ramsay MJ Belza, J Castilla The Norwegian immunisation register – SYSVAK 14 by L Trogstad, G Ung, M Hagerup-Jenssen, I Cappelen, IL Haugen, B Feiring Computerised vaccination register for the Murcia region, Spain, 1991 to 2011 21 by PJ Bernal-González, JA Navarro-Alonso, JJ Pérez-Martín The Danish vaccination register 27 by T Grove Krause, S Jakobsen, M Haarh, K Mølbak Præventis, the immunisation register of the Netherlands: a tool to evaluate the National Immunisation Programme 33 by A van Lier, P Oomen, P de Hoogh, I Drijfhout, B Elsinghorst, J Kemmeren, M Conyn-van Spaendonck, H de Melker Australian immunisation registers: established foundations and opportunities for improvement 39 by LK Chin, NW Crawford, G Rowles, JP Buttery Immunisation registers in Canada: progress made, current situation, and challenges for the future 47 by JA Laroche, AJ Diniz Estimating vaccination coverage in the absence of immunisation registers – the German experience 53 by A Siedler, T Rieck, A Reuss, D Walter, G Poggensee, C Poethko-Müller, S Reitern © Eurosurveillance, 2012 www.eurosurveillance.org 1 Editorials Immunisation registers – important for vaccinated individuals, vaccinators and public health K Johansen ([email protected])1, P L Lopalco1, J Giesecke1 1. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden Citation style for this article: Johansen K, Lopalco PL, Giesecke J. Immunisation registers – important for vaccinated individuals, vaccinators and public health. Euro Surveill. 2012;17(16):pii=20151. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20151 Article submitted on 17 April 2012/ published on 19 April 2012 Vaccines save lives, protect against disability and highlighted during the large immunisation campaigns improve health. Diseases such as smallpox, tuberculo- following the 2009 pandemic. A need for accurate and sis, poliomyelitis, diphtheria, tetanus, pertussis, inva- rapid information on vaccine coverage by target group sive diseases related to Haemophilus influenzae type was identified and individual-level data were requested b and Neisseria meningitides group C infection, that by stakeholders assessing pandemic vaccine safety only half a century ago were all communicable disease and effectiveness. threats to Europeans, are now rare entities or, as in the case of smallpox, eradicated [1]. Consequently, some Most established immunisation registers are able to at of them are almost forgotten by the younger general least (i) collect data on vaccines provided, (ii) gener- public. However, despite the availability of safe and ate reminders and recall vaccination notices for each effective vaccines against measles and rubella and client, (iii) provide official vaccination forms upon the considerable decline in the number of cases in the request for the individual, and (iv) allow vaccination last decades, Europe is still struggling to eliminate coverage assessments. They are therefore also referred them. In 2011 alone, over 30,000 cases of measles and to as Immunisation Information Systems (IISs). Such more than 3,000 cases of rubella were reported in the systems are confidential, population-based and com- European Union (EU) [2]. To help improve coverage with puterised systems that collect vaccination data about recommended vaccines in the childhood and other age residents within a geographic area or with a healthcare or risk group-specific immunisation programmes and provider. IISs are among the most important tools to assess their impact, immunisation registers have been strengthen and improve the performance of immunisa- or are being developed in a number of countries. In tion programmes by consolidating vaccination records a special issue of Eurosurveillance, published in two of all immunisation clients from multiple vaccination parts in this and the following week, country-specific providers. Access to complete records of all previous experiences with established immunisation registers vaccinations makes it easier for the healthcare provider are shared in a series of articles [3-11]. to ensure that individuals receive recommended vac- cines. Systems can also be used to increase and sus- During the upcoming European Immunization Week, the tain high vaccination coverage through identification measles and rubella elimination 2015 goal for Europe of pockets of unvaccinated individuals or groups and will be advocated by EU Member States, the European serve as a basis for tailored vaccination campaigns. Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) through activi- Population-based electronic IISs are preferably created ties such as (i) communication packages [12], (ii) a at birth if possible through linkage with electronic birth video produced in collaboration between the ECDC records. IISs can then be linked to health-outcome and the European news channel Euronews that pre- databases with clinical information and data on medi- sents the severe complications that can occur follow- cal care provided by general practitioners or hospitals. ing measles infections and (iii) a number of national Upon linkage of different data sources, anonymised conferences. While this creates awareness, it is also data can be made available through newly-developed essential to continue the development of technical software that even permits sharing of data across support to the immunisation programmes. One exam- national borders [13]. Linkage of such different data ple of such technical development are immunisation
Recommended publications
  • Combined Live Measles-Mumps Virus Vaccine ROBERT E

    Combined Live Measles-Mumps Virus Vaccine ROBERT E

    Arch Dis Child: first published as 10.1136/adc.48.7.532 on 1 July 1973. Downloaded from Archives of Disease in Childhood, 1973, 48, 532. Combined live measles-mumps virus vaccine ROBERT E. WEIBEL, VICTOR M. VILLAREJOS, GUILLERMO HERNANDEZ C., JOSEPH STOKES, JR.,* EUGENE B. BUYNAK, and MAURICE R. HILLEMAN From the Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Louisiana State University International Center for Medical Research and Training, San Jose, Costa Rica; and the Division of Virus and Cell Biology Research, Merck Institutefor Therapeutic Research, West Point, Pennsylvania, U.S.A. Weibel, R. E., Villarejos, V. M., Hernandez C., G., Stokes, J., Jr., Buynak, E. B., and Hilleman, M. R. (1973). Archives of Disease in Childhood, 48, 532. Combined live measles-mumps virus vaccine. Four lots of combined bivalent live Moraten measles-Jeryl Lynn mumps virus vaccine were administered to a total of 334 children 10 months to 6 years of age, who were initially without antibody against either virus. Overall, 99 % of the children responded serologically to the measles virus and 96 % to mumps. The geometric mean titres were of the same general height as those obtained when the individual vaccines were given alone, and there was no indication of immunological suppression. There was no increase in clinical reaction beyond the mild fever and other reactions that follow the administration of Moraten measles vaccine given alone. The combined measles-mumps vaccine provides a simple means for immunization against both these viruses with no apparent alteration in the immunological or clinical responses. copyright. The need to simplify administration, reduce costs, children) (Mumpsvax) for control purpose.
  • Prevention's New Profits

    Prevention's New Profits

    BACKWATER NO MORE: 26 Expected growth of vaccine industry through 2012: 10.5% // Merck’s vaccine sales in 2007: $4.3 billion // Sales from Wyeth’s Prevnar: $2.4 billion // Interest in vaccines: restored. Prevention’s New Profits by Deborah Kelly and Charles slack ntil the late 1960s, for millions of children, 1953 of trials for a vaccine made him a hero—and the news coming down with mumps meant a week two years later that his vaccine had been deemed ready for U or two away from school with fever, sore mass distribution only increased his stature. Measles, rubella throat and painful swollen glands. But in and several dangerous flu strains fell in quick succession, and a fraction of cases, the consequences were it began to seem as if anything were possible. In 1967, U.S. dire, with complications that could include Surgeon General William H. Stewart announced that it was meningitis, paralysis and sterility. Carried on droplets of sa- time to “close the book on infectious diseases.” liva, the virus was so infectious that a child could get it just by Gradually, though, that unbridled optimism gave way to standing near someone who laughed. With time as the only financial and medical realities. As it turned out, vaccines cure, it seemed to be an affliction that might be with us for- weren’t that great a business proposition for private phar- ever. Then one day mumps messed with the wrong little girl. maceutical companies. Vaccines are hugely labor-intensive to When five-year-old Jeryl Lynn Hilleman awoke with a sore develop, and because most combat a single virus, the process throat and swollen glands, her father, virologist Maurice Hille- must be repeated from scratch for each new strain.
  • Dynamic Transmission Model of Routine Mumps Vaccination in Japan Cambridge.Org/Hyg

    Dynamic Transmission Model of Routine Mumps Vaccination in Japan Cambridge.Org/Hyg

    Epidemiology and Infection Dynamic transmission model of routine mumps vaccination in Japan cambridge.org/hyg Taito Kitano1,2 1 2 Original Paper Department of Neonatal Intensive Care Unit, Nara Prefecture General Medical Center, Nara, Japan and Master of Public Health Degree Program, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA Cite this article: Kitano T (2019). Dynamic transmission model of routine mumps Abstract vaccination in Japan. Epidemiology and Infection 147, e60, 1–8. https://doi.org/ The mumps vaccine is not included in the national immunisation programme (NIP) of 10.1017/S0950268818003230 approximately 80 countries including Japan. To investigate the vaccine’s cost-effectiveness, we developed a dynamic transmission model for routine one- and two-dose mumps vaccin- Received: 5 January 2018 ation programs in Japan. We calculated the incremental cost-effectiveness ratio compared Revised: 10 September 2018 Accepted: 4 November 2018 with a current programme over a projected 50-year period. We created a Japanese population model and performed dynamic simulation to estimate the number of patients enrolled in the Key words: current programme, the routine one-dose programme, and the routine two-dose programme Cost-benefit analysis; immunisation over the next 50 years using the Berkeley Madonna program. We estimated the medical and programme; mumps vaccine; quality-adjusted life years social costs of natural mumps infections and vaccinations to analyse cost-effectiveness. Finally, we performed a sensitivity analysis with parameters including vaccine cost, vaccine efficacy, Author for correspondence: medical costs per case, social costs per case, incidence of adverse events and discount rate. Taito Kitano, E-mail: taito.kitano.0110@gmail.
  • Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine

    Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine

    International Journal of Environmental Research and Public Health Review Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine Shih-Bin Su 1, Hsiao-Liang Chang 2 and Kow-Tong Chen 3,4,* 1 Department of Occupational Medicine, Chi-Mei Medical Center, Tainan 710, Taiwan; [email protected] 2 Department of Surveillance, Centers for Disease Control, Taipei 100, Taiwan; [email protected] 3 Department of Occupational Medicine, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan 701, Taiwan 4 Department of Public Health, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan * Correspondence: [email protected]; Tel.: +886-6-2609926; Fax: +886-6-2606351 Received: 17 January 2020; Accepted: 29 February 2020; Published: 5 March 2020 Abstract: Mumps is an important childhood infectious disease caused by mumps virus (MuV). We reviewed the epidemiology, pathogenesis, and vaccine development of mumps. Previous studies were identified using the key words “mumps” and “epidemiology”, “pathogenesis” or “vaccine” in MEDLINE, PubMed, Embase, Web of Science, and Google Scholar. We excluded the articles that were not published in the English language, manuscripts without abstracts, and opinion articles from the review. The number of cases caused by MuV decreased steeply after the introduction of the mumps vaccine worldwide. In recent years, a global resurgence of mumps cases in developed countries and cases of aseptic meningitis caused by some mumps vaccine strains have renewed the importance of MuV infection worldwide. The performance of mumps vaccination has become an important issue for controlling mumps infections. Vaccine development and routine vaccination are still effective measures to globally reduce the incidence of mumps infections.
  • Live Attenuated Measles Mumps and Rubella Vaccines: an Over View

    Live Attenuated Measles Mumps and Rubella Vaccines: an Over View

    International Journal of Vaccines and Vaccination Live Attenuated Measles Mumps and Rubella Vaccines: An Over View Review Article Abstract Vaccination against Measles, Mumps and Rubella (MMR) of children early in Volume 1 Issue 1 - 2015 life is established worldwide, and recommended by international organisations such as WHO and UNICEF. Elimination of measles and congenital rubella remains Hussein Y Naim* of the major objectives of WHO-UNICEF, albeit the failed plans of eradication Life Sciences and Vaccines Consultant, Switzerland by the early 2000. Therefore, the demand for safe and immunogenic MMR vaccines remains of a high priority in the next decade, both in affluent and *Corresponding author: Hussein Y Naim, Professor of Virology and Immunology, Life Sciences and Vaccines less affluent countries. MMR vaccine has a documented history of safety and Consultant, Bern, Bielstrasse 17, Switzerland, Tel: efficacy irrespective of the conflicting reports on the side effects, which was +49787938790; shown unrelated to the vaccination itself. Therefore, MMR vaccine remains the E-mail: highest saviour of lives worldwide. The use of MMR or the recently developed MMR-V (Varicella) vaccine combination benefited from the established clinical Received: June 16, 2015 | Published: July 07, 2015 surveillance, efficient-technology transfer and proper manufacturing, in addition to the cost effectiveness of these vaccines. Keywords: Measles; Mumps; Rubella; Varicella; MR; MMR; MMRV; Vaccines; Vaccination Abbreviations: MMR: Measles, Mumps and Rubella; 1994 [1] demonstrating that with rigorous approach, including WHO: World Health Organization; SSPE: Subacute Sclerosing a 2 dose schedule and high coverage (97% or more) the target Panencephalitis; PAHO: Pan American Health Organization; of elimination of MMR was achievable.
  • M-M-RVAXPRO, INN-Measles, Mumps, and Rubella Vaccine (Live)

    M-M-RVAXPRO, INN-Measles, Mumps, and Rubella Vaccine (Live)

    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT M-M-RVAXPRO powder and solvent for suspension for injection M-M-RVAXPRO powder and solvent for suspension for injection in pre-filled syringe Measles, mumps and rubella vaccine (live) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution, one dose (0.5 mL) contains: 1 3 Measles virus Enders’ Edmonston strain (live, attenuated) ………..….not less than 1x10 TCID50* 1 3 Mumps virus Jeryl Lynn™ [Level B] strain (live, attenuated)……...…not less than 12.5x10 TCID50* 2 3 Rubella virus Wistar RA 27/3 strain (live, attenuated) …………….….not less than 1x10 TCID50* *50% tissue culture infectious dose 1 produced in chick embryo cells. 2 produced in WI-38 human diploid lung fibroblasts. The vaccine may contain traces of recombinant human albumin (rHA). This vaccine contains a trace amount of neomycin. See section 4.3. Excipient(s) with known effect The vaccine contains 14.5 milligrams of sorbitol per dose. See section 4.4. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and solvent for suspension for injection. Before reconstitution, the powder is a light yellow compact crystalline cake and the solvent is a clear colourless liquid. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications M-M-RVAXPRO is indicated for simultaneous vaccination against measles, mumps and rubella in individuals from 12 months of age (see section 4.2). M-M-RVAXPRO can be administered to infants from 9 months of age under special circumstances (see sections 4.2, 4.4 and 5.1). For use in measles outbreaks, or for post-exposure vaccination, or, for use in previously unvaccinated individuals older than 9 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella, see section 5.1.
  • An Attenuated Live Mumps Virus Vaccine Candidate Expressing F and HN Protein Genes from Genotype G Technology Summary

    An Attenuated Live Mumps Virus Vaccine Candidate Expressing F and HN Protein Genes from Genotype G Technology Summary

    An Attenuated Live Mumps Virus Vaccine Candidate Expressing F and HN Protein Genes from Genotype G Technology Summary Despite near elimination of mumps in the US and other countries that immunize against mumps, there has been a resurgence of the disease, even in highly vaccinated populations. This has resulted in calls for development of new, more efficacious mumps vaccines. However, attenuation of mumps viruses has proven difficult, resulting in the use of some vaccine strains later identified as causing aseptic meningitis in recipients. This has led to vaccine withdrawal, public resistance to vaccination, and even cessation of immunization programs in some countries. There is a need for the development of newer, more efficacious mumps vaccines to address the growing cases of a once dormant disease. This invention is a mumps vaccine candidate engineered for easy adaptability to match changes in the circulating strains, a robust immune response for lasting immunity, and a key mutation to reduce virulence and maintain attenuation. This mumps vaccine candidate is a Jeryl Lynn-based, recombinant virus construct that expresses the genotype G fusion (F) and hemagglutinin-neuraminidase (HN) proteins of circulating mumps strains. It includes a mutation in the viral protein V gene to prevent the expression of a key virulence factor and two restriction enzyme recognition sites to permit efficient exchange of the F and HN protein genes to accommodate the changes in the genotype of the circulating mumps virus. Using in vivo models, it was determined that (1) the HN and F proteins are the major drivers of the anti-mumps virus immune response and (2) matching the vaccine F and HN proteins to those of currently circulating strains would likely improve the duration of immunity.
  • The Role of Vaccines in Elimination and Global Eradication of Measles: a Review of Literature

    The Role of Vaccines in Elimination and Global Eradication of Measles: a Review of Literature

    African Journal of Pharmacy and Pharmacology Vol. 3(9) pp. 413-425, September, 2009 Available online http://www.academicjournals.org/ajpp ISSN 1996-0816 © 2009 Academic Journals Review The role of vaccines in elimination and global eradication of measles: A review of literature I. O. Okonko1*, B. A. Onoja1, A. O. Adedeji2, A. A. Ogun3, A. O. Udeze4, J. Ejembi5, K. N. Garba1, O. C. Egun6 and A. Fowotade7 1Department of Virology, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Ibadan, Nigeria. 2Department of Veterinary Microbiology and Parasitology, Faculty of Veterinary Medicine, University of Ibadan, Ibadan, Nigeria. 3Department of Epidemiology, Medical Statistics and Environmental Health, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, Nigeria. 4Virology Unit, Department of Microbiology, Faculty of Sciences, University of Ilorin, Ilorin, Nigeria. 5Department of Clinical Microbiology, Ahmadu Bello University Teaching Hospital (ABUTH), Zaria, Kaduna State, Nigeria. 6Department of Biochemistry, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Nigeria. 7Department of Medical Microbiology and Parasitology, University of Ilorin Teaching Hospital, Ilorin, Nigeria. Accepted 23 July, 2009 This review summarizes the role of vaccines in elimination and global eradication of measles-a review of literature. Measles eradication is defined as the interruption of measles transmission worldwide as a result of deliberate efforts; intervention methods may no longer be needed. It represents the sum of successful elimination efforts in all countries. Indeed, measles transmission has been interrupted in several countries, reinforcing the view that measles eradication is technically feasible using existing vaccines, laboratory techniques and intervention strategies. However, measles still accounts for 10% of global mortality from all causes among children aged less than 5 years (That is, approximately 1 million deaths annually).
  • Fundamental Thinking

    Fundamental Thinking

    FUNDAMENTAL THINKING UNTESTED: THE INVESTMENT CASE BEHIND THE RACE FOR A CORONAVIRUS VACCINE As the candidates hurtle toward the finish line, modelling the long-term profits for one of the most audacious undertakings in the history of science remains a separate challenge. August 2020 KEY TAKEAWAYS ▪ Its high margins and barriers to entry, low rivalries, and moderate profits over extended periods have historically made vac- cine development one of the most appealing pharamaceutical segments for long-term investors. ▪ Under the urgency of the pandemic, vaccine makers have been asked to compress timelines that in many cases stretched across multiple decades into less than a year. ▪ A successful coronavirus vaccine could be the proof of concept for new models of discovery and development that shake up the old order of how many infectious diseases are tackled. ▪ The companies that achieve durable revenue and profit from the current race will most likely be the companies with the safest and most effective products, not necessarily the companies that obtain approval first. 1 January 11, 2020, the date the genetic sequence of SARS- manufacturer’s favor. In the US, the world’s largest and most CoV2 was published, marked the start of the race for a vac- lucrative vaccine market, the Centers for Disease Control cine. On July 31, Dr. Anthony Fauci, the US’s top infectious negotiates vaccine prices for patients without insurance, disease official testified before Congress that he was “cau- but private insurers and Medicare typically pay 50–100% tiously optimistic” a vaccine would be ready near the end of more.
  • Chapter 15: Mumps; Epidemiology and Prevention of Vaccine

    Chapter 15: Mumps; Epidemiology and Prevention of Vaccine

    Mumps Mariel Marlow, PhD, MPH; Penina Haber, MPH; Carole Hickman, PhD; and Manisha Patel, MD, MS Mumps is an acute viral illness. Parotitis and orchitis were Mumps described by Hippocrates in the 5th century BCE. In 1934, ● Acute viral illness Claud Johnson and Ernest Goodpasture showed that mumps could be transmitted from infected patients to rhesus monkeys ● Parotitis and orchitis described by Hippocrates and demonstrated that mumps was caused by a filterable in 5th century BCE agent present in saliva. This agent was shown to be a virus in 1935. Mumps was one of the most common causes of aseptic ● Viral etiology described meningitis and sensorineural hearing loss in childhood in the by Johnson and Goodpasture United States until the introduction of a vaccine in 1967. In in 1934 1971, mumps vaccine was licensed in the United States as a ● Before vaccine, one of the combined measles, mumps, and rubella (MMR) vaccine. In 2005, most common causes of a combination measles, mumps, rubella, and varicella (MMRV) aseptic meningitis and hearing vaccine was licensed. loss among children and hospitalization among military During World War I, only influenza and gonorrhea were more ● Vaccination led to common than mumps as causes of hospitalization among over 99% reduction in soldiers. A successful 2-dose vaccination program in the United mumps cases States led to a greater than 99% reduction in the number of mumps cases reported annually. However, starting in 2006, there has been an increase in mumps cases and outbreaks, particularly in close-contact settings, with many occurring among fully vaccinated persons. Mumps Virus 15 Mumps Virus Mumps virus is a paramyxovirus in the same group as ● Paramyxovirus (RNA) parainfluenza and Newcastle disease viruses, which produce antibodies that cross-react with mumps virus.
  • Neue Ansätze Bei Impfungen Und Impfschutz

    Neue Ansätze Bei Impfungen Und Impfschutz

    Institute of Pharmaceutical Sciences Functional immune repertoire analysis Neue Ansätze bei Impfungen und Impfschutz Prof. Dr. Klaus Eyer, Eidg. Dipl. Apo. Assistenzprofessor, IPW 17 Dezember 2020, ETH Zürich Impfstoffe gegen COVID-19: Liste der klinischen Versuche Eine Auswahl momentaner Phase III Studien (teilweise erste Genehmigung zur Verwendung in Notfällen (EUA)): - BNT162b2 (mRNA Impfstoff, BioNTech RNA Pharmaceuticals und Pfizer) - mRNA-1273 (mRNA Impfstoff, National Institute of Allergy and Infectious Diseases und Moderna) - AZD1222 (ChAdOx1 nCoV-19) (Impfstoff-Vektor, University of Oxford und Astra Zeneca) - Ad26.COV2.S (Impfstoff-Vektor, Janssen Vaccines & Prevention (Johnson & Johnson)) - Ad5-nCoV (Impfstoff-Vektor, CanSino Biologics) - Gam-COVID-Vac (Impfstoff-Vektor, Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation) - NVX-CoV2373 (rekombinierte Proteine, Novavax) u.a. clinicaltrials.gov Datenstand : 7 Dezember 2020 FIRA 18.12.2020 2 Neue Ansätze bei Impfungen Die aktuelle Pandemie hat viele neue Ansätze für Impfungen an den Markt gebracht Wichtiger Punkt: Beschleunigung vieler Ansätze durch SARS-CoV-2 Teils jahrelange Vorlaufzeit (SARS-CoV-1, Ebola, MERS, etc.) News feature – Nature 2020, Ewen Callaway. FIRA 18.12.2020 3 Hintergrund: SARS-CoV-2 Genetisch verschieden von anderen Coronaviren (>8 Varianten bekannt) Andersen et al., Nature Medicine, 2020. Spike-Protein: Bindung an Angiotensin-Converting- Enyzme II (und andere Proteine) Eintrittspunkt für Infektion Gordon et al., Nature, 2020. Die meisten Ansätze verfolgen eine Strategie beruhend auf dem Spikeprotein und neutralisierenden Antikörpern Ähnlich wie SARS-CoV-1 Weiss und Leibowitz, Advaces in Virus Research, 2011. FIRA 18.12.2020 4 Hintergrund: SARS-CoV-2 Neutralisierende Antikörper: Binden an RBD Blockieren RBD Keine weitere Bindung an ACE-II Keine Infektion Wan et al., Journal of Virology, 2020.
  • Investigation of an Atypically Produced Jeryl Lynn Mumps Vaccine Sarah

    Investigation of an Atypically Produced Jeryl Lynn Mumps Vaccine Sarah

    Investigation of an atypically produced Jeryl Lynn mumps vaccine Sarah Margaret Connaughton BSc (Honours) This thesis is submitted in fulfilment of the requirements of Imperial College London for the degree of Doctor of Philosophy (PhD) Imperial College London Department of Medicine Section of Virology 2015 1 DECLARATION OF ORIGINALITY I, Sarah Margaret Connaughton, declare that the work presented in this thesis is entirely my own, except where appropriately referenced. This work has not previously been submitted, either whole or in part, to Imperial College London or any other University for any other degree. 2 COPYRIGHT DECLARATION The copyright of this thesis rests with the author and is made available under a Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or transmit the thesis on the condition that they attribute it, that they do not use it for commercial purposes and that they do not alter, transform or build upon it. For any reuse or redistribution, researchers must make clear to others the licence terms of this work. 3 ACKNOWLEDGEMENTS First and foremost I would like to sincerely thank my supervisors Dr Silke Schepelmann and Dr Mike Skinner for their guidance and support. Their combined efforts have enabled me to develop independence and self-confidence as a researcher. I would also like to express my thanks to Dr Philip Minor, for his continued interest in this study and for his encouragement and valuable discussions about mumps viruses. This study would not have been possible without funding which was kindly provided by the National Institute for Biological Standards and Control, and there are a number of colleagues who I would also like to thank for providing technical assistance, in particular Mr Shaun Baker, Ms Charlotte Crofts, Ms Rose Curran, Mr Valdemar Gomes and Mr Alan Haynes.